brexpiprazole (Rxulti)

From Aaushi
Jump to navigation Jump to search

Indications

* improves agitation in Alzheimer' disease vs placebo over 12 weeks[2][3]

Contraindications

Dosage

Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg

Dosage adjustment in renal failure

Pharmacokinetics

Adverse effects

* Boxed Warning

Drug interactions

Mechanism of action

More general terms

References

  1. FDA News Release. July 13, 2015 FDA approves new drug to treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454647.htm
  2. 2.0 2.1 Monaco K Rexulti Calms Alzheimer's Dementia-Related Agitation. But atypical antipsychotic disappoints in borderline personality disorder. MedPage Today September 19, 2022 https://www.medpagetoday.com/meetingcoverage/psychcongress/100805
    DePeau-Wilson M Rexulti Works for Agitation in Alzheimer's, Despite Risks, Says FDA Staff. Increased mortality risk consistent with other antipsychotics in elderly dementia patients. MedPage Today April 13, 2023 https://www.medpagetoday.com/neurology/dementia/104000
  3. 3.0 3.1 US Food & Drug Administration News Release. May 11, 2023 FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease. https://www.fda.gov/news-events/press
  4. Lee D, Slomkowski M, Hefting N et al. Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial. JAMA Neurol. 2023 Nov 6:e233810. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37930669 PMCID: PMC10628834 Free PMC article
  5. HIGHLIGHTS OF PRESCRIBING INFORMATION REXULTI <TM> (brexpiprazole) tablets, for oral use https://www.otsuka-us.com/sites/g/files/qhldwo8676/files/media/static/Rexulti-PI.pdf

Database